2580 related articles for article (PubMed ID: 15744147)
1. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
2. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer.
Li D; Jiang W; Bishop JS; Ralston R; O'Malley BW
Clin Cancer Res; 1999 Jun; 5(6):1551-6. PubMed ID: 10389944
[TBL] [Abstract][Full Text] [Related]
3. Combination nonviral cytokine gene therapy for head and neck cancer.
Li D; Zeiders JW; Liu S; Guo M; Xu Y; Bishop JS; O'Malley BW
Laryngoscope; 2001 May; 111(5):815-20. PubMed ID: 11368072
[TBL] [Abstract][Full Text] [Related]
4. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer.
Bray D; Yu SZ; Koprowski H; Rhee J; Kumar S; Pericle F; Suntharalingam M; Van Echo DA; Li D; O'Malley BW
Arch Otolaryngol Head Neck Surg; 2003 Jun; 129(6):618-22. PubMed ID: 12810463
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
6. Combined IL-2 and IL-12 gene therapy for murine head and neck squamous cell carcinoma.
Liu S; Yang H; Liang C
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):323-6. PubMed ID: 12408755
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
8. Effects of combined therapy with interleukin 2 and interleukin 12 gene-transfected tumor vaccine for head and neck carcinoma.
Kimura Y; Mizuno H; Satake K; Tahara H; Tsukuda M
Arch Otolaryngol Head Neck Surg; 2003 Nov; 129(11):1181-5. PubMed ID: 14623747
[TBL] [Abstract][Full Text] [Related]
9. Technology evaluation: gene therapy (IL-2), Valentis Inc.
Morse MA
Curr Opin Mol Ther; 2000 Aug; 2(4):448-52. PubMed ID: 11249776
[TBL] [Abstract][Full Text] [Related]
10. [IL-2 gene and cisplatin combined therapy for head and neck squamous cell carcinoma].
Liu S; Lin Y; Tang S; Yang H; Liang C
Hua Xi Kou Qiang Yi Xue Za Zhi; 2001 Jun; 19(3):191-3. PubMed ID: 12539412
[TBL] [Abstract][Full Text] [Related]
11. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
Horton HM; Dorigo O; Hernandez P; Anderson D; Berek JS; Parker SE
J Immunol; 1999 Dec; 163(12):6378-85. PubMed ID: 10586027
[TBL] [Abstract][Full Text] [Related]
12. [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction].
Yang H; Liu S; Liang C; Peng W
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):9-11, 30. PubMed ID: 15600166
[TBL] [Abstract][Full Text] [Related]
13. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model.
Chang CY; Lee J; Kim EY; Park HJ; Kwon CH; Joh JW; Kim SJ
BMC Cancer; 2007 May; 7():87. PubMed ID: 17519043
[TBL] [Abstract][Full Text] [Related]
15. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
16. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
17. Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model.
Imagawa Y; Satake K; Kato Y; Tahara H; Tsukuda M
Auris Nasus Larynx; 2004 Sep; 31(3):239-45. PubMed ID: 15364358
[TBL] [Abstract][Full Text] [Related]
18. Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site.
Li S; Zhang X; Xia X; Zhou L; Breau R; Suen J; Hanna E
Gene Ther; 2001 Mar; 8(5):400-7. PubMed ID: 11313817
[TBL] [Abstract][Full Text] [Related]
19. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
Tai KF; Chen PJ; Chen DS; Hwang LH
J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model.
Liebau C; Roesel C; Schmidt S; Karreman C; Prisack JB; Bojar H; Merk H; Wolfram N; Baltzer AW
Anticancer Res; 2004; 24(5A):2861-7. PubMed ID: 15517889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
